期刊
VACCINE
卷 27, 期 28, 页码 3735-3743出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.03.083
关键词
Dengue; Viremia; Vaccine
资金
- Founding Research Centers for Emerging and Re-emerging Infectious Diseases
- Ministry of Education, Culture, Sports, Science and Technology (MEXT),Japan
- Research on Emergingand Re-emerging Infectious Diseases
- Ministry of Health and Welfare of Japan
A simple dengue vaccine evaluation system was established using a model of dengue type 2 virus (DENV2) infection in immunocompetent mice. Mice are usually non-permissive hosts, and artificial viremia was therefore created by intraperitoneal injection of K562 cells infected with DENV2. Plasma Virus titers were approximately 4-5 log(10) focus-forming units/ml at 10 h after injection of 1 x 10(7) K562 cells into ICR, ddY and BALB/c mice. ICR mice immunized with an experimental vaccine against DENV2 showed reduced levels of viremia, associated with neutralizing antibody titers. Similarly, ICR mice passively immunized with purified IgG fractions of monoclonal antibodies possessing neutralizing activities also had reduced levels of viremia. However, the degree of viremia reduction differed according to the antibody species. Although some mice developed neurologic symptoms and/or died within 21 days of K562 injection, viremia reduction was considered to be a reliable indicator of the protective capacities of candidate dengue vaccines. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据